E-LIB Suche - Ergebnisse für: MARKS, R.

1

Axicabtagene ciloleucel (Axicel) for relapsed/refractory pr..:

Schubert, M. ; Ayuk, F. A. ; Bethge, W....
Hematological Oncology. 41 (2023) S2 - p. 411-412 , 2023

Link: https://doi.org/10.1002/..

2

Glofitamab plus immunochemotherapy demonstrates durable eff..:

Townsend, W. ; Topp, M. S. ; Dickinson, M....
Hematological Oncology. 41 (2023) S2 - p. 595-597 , 2023

Link: https://doi.org/10.1002/..

3

Castleman's disease in the rheumatological practice; Morbus..:

Schmalzing, M. ; Sander, O. ; Seidl, M....
Zeitschrift für Rheumatologie. 83 (2023) 4 - p. 316-326 , 2023

Link: https://doi.org/10.1007/..

4

Pixantrone containing R‐CPOP as firstline treatment in elde..:

Marks, R. ; Lorenz, K. ; Trepel, M....
Hematological Oncology. 41 (2023) S2 - p. 425-426 , 2023

Link: https://doi.org/10.1002/..

5

Ibrutinib + bortezomib + R‐CHOP for higher‐risk DLBCL: Feas..:

Denker, S. ; Bittner, A. ; Frick, M....
Hematological Oncology. 41 (2023) S2 - p. 424-425 , 2023

Link: https://doi.org/10.1002/..

6

PB2126: R-CPOP AS FIRST LINE TREATMENT FOR DLBCL PATIENTS W..:

Lorenz, K. ; Strüßmann, T. ; Trepel, M....
HemaSphere. 6 (2022) - p. 1997-1998 , 2022

Link: https://doi.org/10.1097/..

7

MA13.09 Time from Immune Checkpoint Inhibitor to Sotorasib ..:

Rakshit, S. ; Bansal, R. ; Potter, A....
Journal of Thoracic Oncology. 17 (2022) 9 - p. S92 , 2022

Link: https://doi.org/10.1016/..

8

P1479: A BASELINE AUDIT OF THE USE A VALIDATED PSYCHOMETRIC..:

Kelleher, K. ; Garcia, V. ; Auturally, R....
HemaSphere. 6 (2022) - p. 1361-1362 , 2022

Link: https://doi.org/10.1097/..

9

EP05.01-011 Real World Outcomes of Durvalumab after Chemora..:

Concepcion, J. Rivera ; Prodduturvar, P. ; Gao, R.W....
Journal of Thoracic Oncology. 17 (2022) 9 - p. S271 , 2022

Link: https://doi.org/10.1016/..

10

OUTCOME DETERMINANTS OF COMMERCIAL CAR‐T CELL THERAPY FOR L..:

Dreger, P. ; Martus, P. ; Holtick, U....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

11

Correction to: Prognostic factors for survival after alloge..:

Greil, C. ; Engelhardt, M. ; Ihorst, G....
Bone Marrow Transplantation. 56 (2021) 8 - p. 2042-2042 , 2021

Link: https://doi.org/10.1038/..

12

Fatigue Crack Growth Monitoring Using Acoustic Emission: A ..:

, In: Lecture Notes in Mechanical Engineering; Advances in Condition Monitoring and Structural Health Monitoring,

Marks, R. ; Stancu, A. ; Soua, S. - p. 551-560 , 2021

Link: https://doi.org/10.1007/..

13

First-line treatment with R-CHOP or rituximab-bendamustine ..:

Pouyiourou, M. ; Meyer, A. ; Stroux, A....
Annals of Hematology. 99 (2020) 12 - p. 2821-2829 , 2020

Link: https://doi.org/10.1007/..

14

Adjuvant Radiation Therapy for Pleural Mesothelioma after E..:

Breen, W. ; Garces, Y. ; Olivier, K....
International Journal of Radiation Oncology*Biology*Physics. 108 (2020) 3 - p. e107-e108 , 2020

Link: https://doi.org/10.1016/..

15

Prognostic factors for survival after allogeneic transplant..:

Greil, C. ; Engelhardt, M. ; Ihorst, G....
Bone Marrow Transplantation. 56 (2020) 4 - p. 841-852 , 2020

Link: https://doi.org/10.1038/..